Abstract PS5-04-12: Inflammatory breast cancer : Monocentric epidemiologic, anatomiclinical features and therapeutic results about 68 patients treated from 2004 to 2024

Abstract Objective: To report the results of a monocentric retrospective serie of inflammatory breast cancers cases observed and treated during a period of 20 years Patients and methods: We collected in a cohort of breast cancers, the cases of inflammatory breast cancer(IBC) subtype diagnosed as T4d AJCC with an evolution of local symptoms in less than 6 months. We analyzed the epidemiologic, anatomic-clinical features, treatments and results. Results: We collected inside a cohort of 2400 breast cancer cases, 68 patients(2.8%), treated for an IBC, having a median age of 42.2 years(27 to 67) with a mean delay of evolution of 5.8 (3 to 6) months. Molecular subtypes are as followed: Luminal= 39/68(58.5%), Her 2 positive 18/69 (26%) and triple negative 11/68(15.5 %). Mean radiological tumor size was 32.5mm(25 to 70mm). Within the 55 patients operated, we observed 10 pathologic complete responses(19%) in 6 cases of luminal B subtype(3 of them her 2+), 3 her 2 positive subtype and 1 triple negative case. We observed 22 relapses with a mean delay of 24 months, msotly metastatic. Nombre de pCr chez les malades opérées =10 (6 luminal , 3 HER2 surexprimé , 1 TN). Overall survival was at 87,14 months, 108 for luminal B subtype, 96,4 for her 2 positive cases and 15.1 months for triple negative cases. Conclusion: Our monocentric serie from Tunisia, reflet’s the epidemiologic and anatomo-clinical features of IBC in our coutry. Patients remain younger than those reported in western countries. We observed a positive trend in terms of survival between patients treated before and after 2010, probably due to the multidisciplinary management and the impact of targeted therapies in her 2 positive cases. Citation Format: M. Boujnah, S. Myriam, A. Haouari, B. Saif, N. Mejri, M. Manai, H. Boussen. Inflammatory breast cancer: Monocentric epidemiologic, anatomiclinical features and therapeutic results about 68 patients treated from 2004 to 2024 [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS5-04-12.